256 related articles for article (PubMed ID: 25091085)
1. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
Ragland DA; Nalivaika EA; Nalam MN; Prachanronarong KL; Cao H; Bandaranayake RM; Cai Y; Kurt-Yilmaz N; Schiffer CA
J Am Chem Soc; 2014 Aug; 136(34):11956-63. PubMed ID: 25091085
[TBL] [Abstract][Full Text] [Related]
2. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
3. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
[TBL] [Abstract][Full Text] [Related]
4. Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.
Henes M; Lockbaum GJ; Kosovrasti K; Leidner F; Nachum GS; Nalivaika EA; Lee SK; Spielvogel E; Zhou S; Swanstrom R; Bolon DNA; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2019 Nov; 14(11):2441-2452. PubMed ID: 31361460
[TBL] [Abstract][Full Text] [Related]
5. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
6. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Yu Y; Wang J; Shao Q; Shi J; Zhu W
Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849
[TBL] [Abstract][Full Text] [Related]
7. Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Kneller DW; Agniswamy J; Harrison RW; Weber IT
FEBS J; 2020 Aug; 287(15):3235-3254. PubMed ID: 31920003
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
[TBL] [Abstract][Full Text] [Related]
9. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
Cai Y; Schiffer C
Methods Mol Biol; 2012; 819():551-60. PubMed ID: 22183557
[TBL] [Abstract][Full Text] [Related]
10. Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.
Henes M; Kosovrasti K; Lockbaum GJ; Leidner F; Nachum GS; Nalivaika EA; Bolon DNA; Kurt Yilmaz N; Schiffer CA; Whitfield TW
Biochemistry; 2019 Sep; 58(35):3711-3726. PubMed ID: 31386353
[TBL] [Abstract][Full Text] [Related]
11. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
Lockbaum GJ; Leidner F; Rusere LN; Henes M; Kosovrasti K; Nachum GS; Nalivaika EA; Ali A; Yilmaz NK; Schiffer CA
ACS Infect Dis; 2019 Feb; 5(2):316-325. PubMed ID: 30543749
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient-derived HIV-1 proteases.
Kožíšek M; Lepšík M; Grantz Šašková K; Brynda J; Konvalinka J; Rezáčová P
FEBS J; 2014 Apr; 281(7):1834-47. PubMed ID: 24785545
[TBL] [Abstract][Full Text] [Related]
13. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
14. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
[TBL] [Abstract][Full Text] [Related]
15. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
16. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
Su CT; Ling WL; Lua WH; Haw YX; Gan SK
BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
[TBL] [Abstract][Full Text] [Related]
17. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
[TBL] [Abstract][Full Text] [Related]
18. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
19. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
[TBL] [Abstract][Full Text] [Related]
20. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
